Trial reportBone marrow transplantation2015
A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.Immunotherapy · 2017Pooled it
- Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Trial
- Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.Journal of hematology & oncology · 2017Trial
- Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease.Annals of hematology · 2026Article
- Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High-Risk Hematological Malignancies.European journal of haematology · 2026Article
- Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis.Annals of hematology · 2026Article
- Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025Review
- Article
- Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.Frontiers in immunology · 2024Review
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Frontiers in immunology · 2024Review
- Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation.International journal of hematology · 2023Review
- Article
- Article
- Article
- PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.Bone marrow transplantation · 2021Review
- Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation.American journal of cancer research · 2021Article
- Review
- A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment.Journal of clinical medicine · 2020Article
- HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center.Stem cell research & therapy · 2020Observational
- [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DLIs are frequently used following haematopoietic SCT (HSCT) in patients with risk of relapse but data on GVHD following DLI are scarce. We report on 68 patients who received DLI following HSCT. Most patients developed GVHD following DLI (71%), which was acute in 22 patients (32%) almost half of whom had grade III-IV acute GVHD (aGVHD). Thirty patients (44%) developed cGVHD which followed aGVHD in four patients and was graded severe in nine patients. Corticosteroids were the most common first-line therapy for both acute and chronic GVHD. A wide range of second/third-line agents included cyclosporin, mycophenolate, tacrolimus, imatinib, infliximab and ECP. Relapse of initial malignancy occurred in 37%. Relapse was significantly less frequent in those receiving pre-emptive DLI. Relapse rates were also lower in those with GVHD (31%) than those without GVHD (50%), but this did not reach statistical significance. At 55 months post DLI, 34% of patients had died most commonly from relapse and 22% had on-going GVHD. Although GVHD was an important cause of morbidity post DLI (71%), only 6% died from GVHD. Although most patients develop GVHD post DLI and may require consecutive therapies, mortality from GVHD is infrequent. DLI remains an important option for relapse post transplant and manipulation of the GVT effect needs to be optimised to induce remission without morbidity from GVHD.
Indexed as
Identifiers
25310308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.